The relevant clinic pathological characteristics screened by multivariable analysis were used to assess the influence of CD39 expression on luminal BC patients, high CD39 was an independent prognostic factor associated with poor OS in the luminal molecular type subgroup (training: P = 0.0185; HR: 2.310, 95% CI: 1.151–4.637, validation: P = 0.0458; HR: 1.602, 95% CI: 1.009–2.543, Table 3). This evidence concerns the gene ENTPD1 and breast cancer.